PLATELET-DERIVED GROWTH-FACTOR (PDGF) IN PLASMA OF BREAST-CANCER PATIENTS - CORRELATION WITH STAGE AND RATE OF PROGRESSION
PLATELET-DERIVED GROWTH-FACTOR (PDGF) IN PLASMA OF BREAST-CANCER PATIENTS - CORRELATION WITH STAGE AND RATE OF PROGRESSION
复制标题
DOI：
10.1007/bf01833352
复制
发表时间：
1991-12-01
影响因子：
3.8
通讯作者：
BEZWODA, WR
中科院分区：
文献类型：
--
作者：
ARIAD, S;SEYMOUR, L;BEZWODA, WR
通过特定的放射免疫测定法，测量了 58 名女性乳腺癌患者和 9 名正常女性对照受试者的血小板衍生生长因子 (PDGF) 的血浆水平。正常对照受试者中的水平均低于测定的检测下限（1.56 fmol/100-mu-l 血浆）。 17 名 2 期乳腺癌患者中有两人 (12%) 的血浆水平可检测到。在 4 期乳腺癌患者中，13/41 (32%) 的水平显着升高（> 检测灵敏度下限的 2 倍）。 PDGF水平升高的患者的转移程度显着更高，且生存期显着缩短。除了作为侵袭性大体积乳腺癌的标志物之外，PDGF 还可能参与某些转移性乳腺肿瘤生长的加速。
Plasma levels of platelet-derived growth factor (PDGF) were measured in 58 female patients with breast canCer and in 9 normal female control subjects by means of a specific radioimmunoassay. Levels in normal control subjects were all below the lower limits of detection by the assay (1.56 fmol/100-mu-l plasma). Two of 17 (12%) patients with stage 2 breast cancer had detectable plasma levels. Among patients with Stage 4 breast cancer 13/41 (32%) had significantly elevated levels (> 2 times the lower limit of sensitivity of the assay). Patients with elevated PDGF levels had a significantly greater degree of metastatic involvement and significantly shorter survival. Apart from being a marker of aggressive high bulk breast cancer, PDGF may be involved in the acceleration of growth of some metastatic breast tumors.